Heart and Vessels

, Volume 34, Issue 2, pp 368–374 | Cite as

Does administration of eicosapentaenoic acid increase soluble thrombomodulin level in statin-treated patients with stable coronary artery disease?

  • Shigemasa TaniEmail author
  • Rei Matsuo
  • Atsushi Hirayama
Short Communication


Interventions targeting the serum eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio could be useful for the prevention of coronary artery disease (CAD). Few data exist regarding the effects of administration of EPA on the serum levels of soluble thrombomodulin (sTM) as a marker of endothelial damage, or on the relationship between the sTM and EPA/AA ratio in patients with CAD receiving statin treatment. We assigned stable CAD patients already receiving statin therapy to an EPA group (1800 mg/day: n = 50) or control group (n = 50). A significant increase of the sTM level was observed in the EPA group as compared to that in the control group 0.40 (0.10/0.70) FU/mL vs. 0.20 (0/0.40) FU/mL, p = 0.004 at the 6-month follow-up examination. Multivariate regression analysis after adjustments for coronary risk factors and changes of the serum lipid levels identified an increased EPA/AA ratio as an independent predictor of increased serum sTM level (β = 0.244, p = 0.02). The results suggest that an increased sTM level caused by additional administration of EPA to statin might be associated with an increased EPA/AA ratio. The increase of the serum sTM after administration of EPA might reflect an increase of the TM expression on the endothelial surface rather than endothelial damage in CAD patients under statin treatment.

Clinical Trial Registration Information UMIN (, Study ID: UMIN000010452.


Eicosapentaenoic acid Soluble thrombomodulin Vascular endothelial cell 



This work was supported by KAKENHI Grant number 23590757 of the Japan Society for the Promotion of Science (JSPS). The authors would like to thank International Medical Information Center ( for the English language review. The authors would also like to thank Mr. Gary Cooper for his help in editing the English manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Mozaffarian D, Wu JH (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58:2047–2067CrossRefGoogle Scholar
  2. 2.
    Tani S, Matsuo R, Kawauchi K, Yagi T, Atsumi W, Hirayama A (2018) A cross-sectional and longitudinal study between association of n-3 polyunsaturated fatty acids derived from fish consumption and high-density lipoprotein heterogeneity. Heart Vessels 33:470–480CrossRefGoogle Scholar
  3. 3.
    Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369:1090–1098CrossRefGoogle Scholar
  4. 4.
    Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y, Investigators JELIS (2011) Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb 18:99–107CrossRefGoogle Scholar
  5. 5.
    Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M, Yamamoto M, Shinozaki T, Miyauchi K, Nagao K, Hirayama A, Yoshimura M, Komuro I, Nagai R, Daida H (2014) Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome. Am J Cardiol 113:441–445CrossRefGoogle Scholar
  6. 6.
    Tani S, Nagao K, Kawauchi K, Yagi T, Atsumi W, Matsuo R, Hirayama A (2017) The ratio of eicosapentaenoic acid (EPA) to arachidonic acid may be a residual risk marker in stable coronary artery disease patients receiving treatment with statin following EPA therapy. Am J Cardiovasc Drugs 17:409–420CrossRefGoogle Scholar
  7. 7.
    Takahashi M, Ando J, Shimada K, Nishizaki Y, Tani S, Ogawa T, Yamamoto M, Nagao K, Hirayama A, Yoshimura M, Daida H, Nagai R, Komuro I (2017) The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated with diabetes mellitus in patients with prior myocardial infarction: a multicenter cross-sectional study. BMC Cardiovasc Disord 17:41CrossRefGoogle Scholar
  8. 8.
    Tani S, Takahashi A, Nagao K, Hirayama A (2015) Association of fish consumption-derived ratio of serum n-3 to n-6 polyunsaturated fatty acids and cardiovascular risk with the prevalence of coronary artery disease. Int Heart J 56:260–268CrossRefGoogle Scholar
  9. 9.
    Sakamoto A, Saotome M, Hosoya N, Kageyama S, Yoshizaki T, Takeuchi R, Murata K, Nawada R, Onodera T, Takizawa A, Satoh H, Hayashi H (2016) Aberrant serum polyunsaturated fatty acids profile is relevant with acute coronary syndrome. Heart Vessels 31:1209–1217CrossRefGoogle Scholar
  10. 10.
    Sadler JE (1997) Thrombomodulin structure and function. Thromb Haemost 78:392–395CrossRefGoogle Scholar
  11. 11.
    Ishii H, Majerus PW (1985) Thrombomodulin is present in human plasma and urine. J Clin Invest 76:2178–2181CrossRefGoogle Scholar
  12. 12.
    Califano F, Giovanniello T, Pantone P, Campana E, Parlapiano C, Alegiani F, Vincentelli GM, Turchetti P (2000) Clinical importance of thrombomodulin serum levels. Eur Rev Med Pharmacol Sci 4:59–66Google Scholar
  13. 13.
    Martin FA, Murphy RP, Cummins PM (2013) Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects. Am J Physiol Heart Circ Physiol 304:H1585–H1597CrossRefGoogle Scholar
  14. 14.
    Blann AD, Amiral J, McCollum CN (1997) Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 59:115–120CrossRefGoogle Scholar
  15. 15.
    Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN (1997) Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 27:916–921CrossRefGoogle Scholar
  16. 16.
    Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, Chambless LE, Wu KK (1999) Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 353:1729–1734CrossRefGoogle Scholar
  17. 17.
    Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA (1997) Thrombomodulin gene mutations associated with myocardial infarction. Circulation 96:15–18CrossRefGoogle Scholar
  18. 18.
    Ohlin AK, Norlund L, Marlar RA (1997) Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 78:396–400CrossRefGoogle Scholar
  19. 19.
    Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA (2001) AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 38:1581–1583CrossRefGoogle Scholar
  20. 20.
    Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41–50CrossRefGoogle Scholar
  21. 21.
    Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J (2003) Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 36:499–504CrossRefGoogle Scholar
  22. 22.
    Lin SJ, Hsieh FY, Chen YH, Lin CC, Kuan II, Wang SH, Wu CC, Chien HF, Lin FY, Chen YL (2009) Atorvastatin induces thrombomodulin expression in the aorta of cholesterol-fed rabbits and in TNFalpha-treated human aortic endothelial cells. Histol Histopathol 24:1147–1159Google Scholar
  23. 23.
    Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M (2003) Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14:575–585CrossRefGoogle Scholar
  24. 24.
    Wu KK, Matijevic-Aleksic N (2000) Thrombomodulin a linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis. Ann Med 32(Suppl 1):73–77Google Scholar
  25. 25.
    Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T (2015) Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost 13:508–519CrossRefGoogle Scholar
  26. 26.
    Li YH, Shi GY, Wu HL (2009) Thrombomodulin in the treatment of atherothrombotic diseases. Front Biosci (Schol Ed) 1:33–38CrossRefGoogle Scholar
  27. 27.
    Borow KM, Nelson JR, Mason RP (2015) Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis 242:357–366CrossRefGoogle Scholar
  28. 28.
    Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Michishita I (2013) Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. Am J Cardiol 111:6–11CrossRefGoogle Scholar
  29. 29.
    Barcelli U, Glas-Greenwalt P, Pollak VE (1985) Enhancing effect of dietary supplementation with omega-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res 39:307–312CrossRefGoogle Scholar
  30. 30.
    Siasos G, Tousoulis D, Oikonomou E, Zaromitidou M, Verveniotis A, Plastiras A, Kioufis S, Maniatis K, Miliou A, Siasou Z, Stefanadis C, Papavassiliou AG (2013) Effects of Ω-3 fatty acids on endothelial function, arterial wall properties, inflammatory and fibrinolytic status in smokers: a cross over study. Int J Cardiol 166:340–346CrossRefGoogle Scholar
  31. 31.
    Boberg M, Pollare T, Siegbahn A, Vessby B (1992) Supplementation with n-3 fatty acids reduces triglycerides but increases PAI-1 in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 22:645–650CrossRefGoogle Scholar
  32. 32.
    Phang M, Lincz LF, Garg ML (2013) Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women. J Nutr 143:457–463CrossRefGoogle Scholar
  33. 33.
    Kawauchi K, Tani S, Nagao K, Hirayama A (2014) Association of n-3 polyunsaturated fatty acids with soluble thrombomodulin as a marker of endothelial damage:cross-sectional pilot study. J Cardiol 64:312–317CrossRefGoogle Scholar
  34. 34.
    Superko HR, Superko SM, Nasir K, Agatston A, Garrett BC (2013) Omega-3 fatty acid blood levels: clinical significance and controversy. Circulation 128:2154–2161CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Health Planning CenterNihon University HospitalTokyoJapan
  2. 2.Department of CardiologyNihon University HospitalTokyoJapan
  3. 3.Division of Cardiology, Department of MedicineNihon University School of MedicineTokyoJapan

Personalised recommendations